Clinical Trial Update: Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update on genetically engineered CAR T cells (EGFRt/19-28z/IL-12) for relapsed or refractory CD19+ hematologic malignancies; the study ha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• High-grade B-cell Lymphoma
• Mantle Cell Lymphoma
• Transformed Chronic Lymphocytic Leukemia
• Transformed Follicular Lymphoma to Diffuse Large B-cell Lymphoma

Drugs mentioned

• EGFRt/19-28z/IL-12 CAR T Cells

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Status: TERMINATED